According to a latest news report, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company (CDMO), has recently launched “Lobeglitazone,” an anti-diabetic drug in India. The news was reported in the Economic Times Health World.
The company said that this novel drug was launched after getting the nod from the Drug Controller-General of India (DCGI). Lobeglitazone is specially formulated for people with type-2 diabetes who secrete insulin but are not able to utilize it due to poor insulin sensitivity. This one-of-a-kind medication has a relatively low risk of hypoglycemia. It helps type-2 diabetic patients to improve their pancreatic beta-cell function.
Akums claims to be the first CDMO to launch lobeglitazone tablets in the Indian market. The drug is a result of in-depth research and development and is known to reduce blood sugar levels, lower hemoglobin A1C (HbA1C) levels, and improve lipid and liver profiles. Akums is known for its focus on innovation to improve and offer better treatments to the patients.
Source: Akums gets DCGI nod to launch anti-diabetic drug Lobeglitazone in India. ET HealthWorld. 6 February, 2023. https://health.economictimes.indiatimes.com/news/pharma/akums-gets-dcgi-nod-to-launch-anti-diabetic-drug-lobeglitazone-in-india/97646272.
